Scpharmaceuticals (NASDAQ:SCPH) announced its quarterly earnings results on Tuesday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.27), Bloomberg Earnings reports.
Scpharmaceuticals stock traded up $0.48 on Thursday, reaching $12.96. 83,297 shares of the company’s stock traded hands, compared to its average volume of 49,273. Scpharmaceuticals has a 52-week low of $11.50 and a 52-week high of $18.17.
Several equities analysts recently issued reports on SCPH shares. BMO Capital Markets started coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set an “outperform” rating and a $24.00 price target for the company. Leerink Swann started coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set an “outperform” rating and a $20.00 price target for the company. Jefferies Group started coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $23.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Scpharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th.
scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.